Skip to main content

Table 3 Surgical Outcomes of the Three Study Cohorts with Case-Matched

From: Risk of postoperative complications among ulcerative colitis patients treated preoperatively with vedolizumab: a matched case-control study

 None
(n = 54)
Anti-TNF
(n = 74)
Vedolizumab
(n = 25)
p
Overall morbidity20 (37)33 (45)11 (44)0.67
Infectious complications11 (20)8 (11)2 (8)0.20
Pelvic abscess02 (3)1 (4) 
Wound infection9 (17)5 (8)1 (4) 
Urinary tract1 (2)00 
Pneumonia1 (2)00 
Post-operative Ileus
Grade I5 (9)12 (16)9 (36)0.01
Grade II3(6)4(5)2(8)0.89
Other morbidity4 (8)13 (18)1(4)0.14
Postoperative stay (d)6 (5–8)6 (5–8)5 (3–9)0.17
30-day readmission7 (13)11 (15)1 (4)0.36
  1. All values expressed as median (range) or n (%)
  2. TNF tumor necrosis factor